{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:56:15Z","timestamp":1791021375259,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00259-019-04601-3","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T14:03:01Z","timestamp":1576332181000},"page":"895-906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-7383","authenticated-orcid":false,"given":"Lisa","family":"Bodei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviral","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter A.","family":"van der Zwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Severi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignat A.","family":"Drozdov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Malczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik J.","family":"Kwekkeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irvin M.","family":"Modlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,14]]},"reference":[{"issue":"1","key":"4601_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.hoc.2015.09.009","volume":"30","author":"DJ Kwekkeboom","year":"2016","unstructured":"Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):179\u201391. https:\/\/doi.org\/10.1016\/j.hoc.2015.09.009.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"4601_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"12","key":"4601_CR3","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"4601_CR4","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4601_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/ERC-16-0524","volume":"24","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, et al. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Endocr Relat Cancer. 2017;24(5):243\u201351. https:\/\/doi.org\/10.1530\/ERC-16-0524.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"4601_CR6","first-page":"1155","volume":"45","author":"L Bodei","year":"2018","unstructured":"Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. EJNMMI. 2018;45(7):1155\u201369.","journal-title":"EJNMMI"},{"issue":"11","key":"4601_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1373\/clinchem.2014.231712","volume":"61","author":"X Zhao","year":"2015","unstructured":"Zhao X, Modur V, Carayannopoulos LN, Laterza OF. Biomarkers in pharmaceutical research. Clin Chem. 2015;61(11):1343\u201353. https:\/\/doi.org\/10.1373\/clinchem.2014.231712.","journal-title":"Clin Chem"},{"issue":"1","key":"4601_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1186\/s12885-016-2886-9","volume":"16","author":"S Amin","year":"2016","unstructured":"Amin S, Bathe OF. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer. 2016;16(1):850. https:\/\/doi.org\/10.1186\/s12885-016-2886-9.","journal-title":"BMC Cancer"},{"issue":"6","key":"4601_CR9","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/RLU.0b013e31823926e5","volume":"37","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, et al. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med. 2012;37(6):e141\u20137. https:\/\/doi.org\/10.1097\/RLU.0b013e31823926e5.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"4601_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349\u201356.","journal-title":"J Nucl Med"},{"issue":"6","key":"4601_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrgastro.2017.26","volume":"14","author":"M Kidd","year":"2017","unstructured":"Kidd M, Modlin IM. Therapy: the role of liquid biopsies to manage and predict PRRT for NETs. Nat Rev Gastroenterol Hepatol. 2017;14(6):331\u20132.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4601_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2967\/jnumed.118.219386","volume":"60","author":"L Bodei","year":"2019","unstructured":"Bodei L, Herrmann K, Baum RP, Kidd M, Malczewska A, Modlin IM. Caveat emptor: let our acclaim of the apotheosis of PRRT not blind us to the error of Prometheus. J Nucl Med. 2019;60(1):7\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.219386.","journal-title":"J Nucl Med"},{"issue":"5","key":"4601_CR13","doi-asserted-by":"publisher","first-page":"e63364","DOI":"10.1371\/journal.pone.0063364","volume":"8","author":"Irvin M. Modlin","year":"2013","unstructured":"Modlin I, Drozdov I, Kidd M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. Plos One. 2013:e63364.","journal-title":"PLoS ONE"},{"issue":"4","key":"4601_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1530\/ERC-15-0092","volume":"22","author":"M Kidd","year":"2015","unstructured":"Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561\u201375. https:\/\/doi.org\/10.1530\/ERC-15-0092.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"4601_CR15","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1158\/078-0432.CCR-17-3378","volume":"24","author":"F Chen","year":"2018","unstructured":"Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, et al. Pan-cancer molecular classes transcending tumor lineage across 32 cancer types, multiple data platforms, and over 10,000 cases. Clin Cancer Res. 2018;24(9):2182\u201393. https:\/\/doi.org\/10.1158\/078-0432.CCR-17-3378.","journal-title":"Clin Cancer Res"},{"key":"4601_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fendo.2018.00740","volume":"9","author":"MJC van Treijen","year":"2018","unstructured":"van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, et al. Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study. Front Endocrinol (Lausanne). 2018;9:740. https:\/\/doi.org\/10.3389\/fendo.2018.00740 eCollection 2018.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"4601_CR17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000497037","volume":"108","author":"A Malczewska","year":"2019","unstructured":"Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk A, Filosso PL, et al. NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and identifies progressive disease neuroendocrinology. Neuroendocrinology. 2019;108(3):219\u201331.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"4601_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1634\/theoncologist.2017-0623","volume":"24","author":"E Liu","year":"2019","unstructured":"Liu E, Paulson S, Gulati A, Freudman J, Kafer S, Wickremesinghe P, et al. Assessment of NETest clinical utility in a US registry-based study. Oncologist. 2019;24(6):783\u201390.","journal-title":"Oncologist"},{"issue":"11","key":"4601_CR19","doi-asserted-by":"publisher","first-page":"E1437","DOI":"10.1210\/jc.2015-2792","volume":"100","author":"JB Cwikla","year":"2015","unstructured":"Cwikla JB, Bodei L, Kolasinska-Cwikla A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100(11):E1437\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"4601_CR20","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.18632\/oncotarget.23820","volume":"9","author":"M Kidd","year":"2017","unstructured":"Kidd M, Modlin I, Drozdov I, Aslanian H, Bodei L, Matar S, et al. A liquid biopsy for bronchopulmonary\/lung carcinoid diagnosis. Oncotarget. 2017;9(6):7182\u201396.","journal-title":"Oncotarget"},{"issue":"4","key":"4601_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1530\/EC-19-0030","volume":"8","author":"Anna Malczewska","year":"2019","unstructured":"Malczewska A, Makulik K, Witkowska M, Bocian A, Walter A, Zaj\u0119cki W, et al. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and accurately correlates with anatomical and functional imaging. Endocr Connect. 2019. https:\/\/doi.org\/10.1530\/EC-19-0030.","journal-title":"Endocrine Connections"},{"issue":"5","key":"4601_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00259-015-3250-z","volume":"43","author":"L Bodei","year":"2016","unstructured":"Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43(5):839\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3250-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"4601_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.suronc.2015.02.001","volume":"24","author":"Y. Nancy You","year":"2015","unstructured":"You YN, Rustin RB, Sullivan JD. Oncotype DX((R)) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: a review of the evidence. Surg Oncol. 2015;24(2):61\u20136. https:\/\/doi.org\/10.1016\/j.suronc.2015.02.001. Epub Feb 14.","journal-title":"Surgical Oncology"},{"issue":"2","key":"4601_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000446025","volume":"104","author":"M Pavel","year":"2017","unstructured":"Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive. Neuroendocrinology. 2017;104(2):170\u201382.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"4601_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1210\/jc.2018-01804","volume":"104","author":"A Malczewska","year":"2019","unstructured":"Malczewska A, Bodei L, Kidd M, Modlin IM. Blood mRNA measurement (NETest) for neuroendocrine tumor diagnosis of image-negative liver metastatic disease. J Clin Endocrinol Metab. 2019;104(3):867\u201372. https:\/\/doi.org\/10.1210\/jc.2018-01804.","journal-title":"J Clin Endocrinol Metab"},{"key":"4601_CR26","doi-asserted-by":"publisher","first-page":"e435046","DOI":"10.1016\/S1470-2045(15)00186-2","volume":"16","author":"K Oberg","year":"2015","unstructured":"Oberg K, Modlin I, DeHerder W, Pavel M, Klimstra D, Frilling A, et al. Biomarkers for neuroendocrine tumor disease: a delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes. Lancet Oncol. 2015;16:e435046.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4601_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MED.0000000000000215","volume":"23","author":"M Kidd","year":"2016","unstructured":"Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes. 2016;23(1):28\u201337. https:\/\/doi.org\/10.1097\/MED.0000000000000215.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"23","key":"4601_CR28","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","volume":"22","author":"MA Kouvaraki","year":"2004","unstructured":"Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762\u201371. https:\/\/doi.org\/10.1200\/JCO.2004.04.024.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4601_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006.EpubSep12","volume":"95","author":"MO Oksuz","year":"2014","unstructured":"Oksuz MO, Winter L, Pfannenberg C, Reischl G, Mussig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289\u2013300. https:\/\/doi.org\/10.1016\/j.diii.2013.07.006.EpubSep12.","journal-title":"Diagn Interv Imaging"},{"issue":"2","key":"4601_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grunwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55(2):183\u201390. https:\/\/doi.org\/10.2967\/jnumed.113.125336.","journal-title":"J Nucl Med"},{"issue":"5","key":"4601_CR31","doi-asserted-by":"publisher","first-page":"448","DOI":"10.7150\/thno.3931","volume":"2","author":"K Oberg","year":"2012","unstructured":"Oberg K. Molecular Imaging Radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics. 2012;2(5):448\u201358.","journal-title":"Theranostics."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04601-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04601-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04601-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T19:42:06Z","timestamp":1607802126000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04601-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,14]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4601"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04601-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,14]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All human participant procedures were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent: Informed consent was obtained from all participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"LB, RPB, and GP\u2014consultancy fees from Ipsen and Advanced Accelerator Applications unrelated to the submitted work (AAA). EPK and DJK\u2014support from AAA unrelated to the submitted work. RPB\u2014support from Ipsen, ROTOP Pharmaka, and OctreoPharm Sciences unrelated to the work. MK\u2014employed by Wren Laboratories. IMM and IAD\u2014consultants for Wren Laboratories. No conflicts for AS, WAvZ, SS, or AM.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}